Table 6.

Phase II studies of S-1 and radiotherapy for locally advanced pancreatic cancer

Ref.	n	ORR	PFS/TTP (mo)	MST (mo)
Sudo et al[47]	34	41%	8.7	16.8
Ikeda et al[48]	60	27%	9.7	16.2
Shinchi et al[49]	50	30%	6.7	14.3
Kim et al[50]	25	24%	6.5	12.9

PFS: Progression-free survival; TTP: Time to progression; MST: Median survival time; ORR: Objective response rate.